Is There a Significant Difference in Acute Kidney Injury Incidence Among Patients Treated with Vancomycin Combined with Cefepime or Meropenem?

BACKGROUND: Acute kidney injuries (AKIs) are common among patients receiving concomitant vancomycin (VAN) and piperacillin-tazobactam, especially compared with cefepime (FEP) with vancomycin. It is unknown if there is a significant difference between therapeutic alternatives to piperacillin-tazobact...

Descripción completa

Detalles Bibliográficos
Autores principales: Rutter, W Cliff, Burgess, David S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631476/
http://dx.doi.org/10.1093/ofid/ofx163.803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631476/
http://dx.doi.org/10.1093/ofid/ofx163.803

Ejemplares similares